BioSpace

Court Rejects Two Moderna Defenses in mRNA Vaccine Patent Row With Arbutus

Arbutus alleges that Moderna’s COVID-19 vaccine infringes on patents protecting its lipid nanoparticle delivery technology.

Moderna got a win from the FDA, but political headwinds remain a concern for vaccine makers

The whiplash over a new potential flu vaccine from Moderna, which went from rejected to approved for review in a matter of days, has illustrated a new reality plaguing the Cambridge biotech company and other vaccine makers: Political headwinds are now an unavoidable and unpredictable factor in their business model.

Stocks to Watch Wednesday: Sandisk, Moderna, Caesars, Kenvue

The FDA agreed to review Moderna's seasonal flu shot after the vaccine maker said it would run extra tests in the elderly.

Health rounds: Moderna combo flu/COVID vaccine succeeds in mid-stage trial

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) Feb 18 (Reuters) - A two-in-one mRNA vaccine developed by Moderna that targets seasonal influenza and COVID-19 produced robust and durable immune responses without safety concerns in a small mid-stage trial,

Moderna Shares Gain After New Flu Vaccine Clears Regulatory Hurdle

Shares of Moderna climbed after the Food and Drug Administration accepted for review a revised application for the company's new flu vaccine. The stock gained 6.7%, to $46.89, in premarket trading Wednesday. Through Tuesday's close, shares are up 22% over the past year.

Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission

Following a Type A meeting, the FDA's Center for Biologics Evaluation and Research has notified Moderna that its biologics license application for mRNA-1010 will proceed to review